Table 3.
Characterization of targeted therapy.
| Patient Characteristics | Total Cohort n = 242 |
CTRL n = 160 |
COMB n = 82 |
Significance p-Value |
|---|---|---|---|---|
| CDKi, n (%) | 26 (10.7) | 17 (10.6) | 9 (11.0) | 1.0 |
| abemaciclib, n (%) | 4 (1.7) | 1 (0.6) | 3 (3.7) | |
| palbociclib, n (%) | 18 (7.4) | 14 (8.8) | 4 (4.9) | |
| ribociclib, n (%) | 5 (2.1) | 3 (1.9) | 2 (2.4) | |
| mAB, n (%) | 206 (84.1) | 136 (85.0) | 70 (85.4) | 1.0 |
| bevacizumab, n (%) | 47 (19.4) | 35 (2.19) | 12 (14.6) | |
| denusomab, n (%) | 8 (3.3) | 4 (2.5) | 4 (4.9) | |
| glembatumumab, n (%) | 1 (0.4) | 1 (0.6) | 0 | |
| pertuzumab, n (%) | 2 (0.8) | 1 (0.6) | 1 (1.2) | |
| pertuzumab/trastuzumab, n (%) | 62 (25.6) | 30 (18.8) | 32 (39.0) | |
| rituximab, n (%) | 2 (0.8) | 1 (0.6) | 1 (1.2) | |
| trastuzumab, n (%) | 74 (30.6) | 55 (34.4) | 19 (23.2) | |
| trastuzumab-emtasin, n (%) | 3 (1.2) | 3 (1.9) | 0 | |
| ICI, n (%) | 13 (5.4) | 8 (5) | 5 (6.1) | 1.0 |
| atezolizumab, n (%) | 11 (4.5) | 7 (4.4) | 4 (4.9) | |
| pembrolizumab, n (%) | 2 (0.8) | 1 (0.6) | 1 (1.2) | |
| PARPi, n (%) | 4 (1.7) | 3 (1.9) | 1 (1.2) | 1.0 |
| niraparib, n (%) | 1 (0.4) | 1 (0.6) | 0 | |
| olaparib, n (%) | 3 (1.2) | 2 (1.3) | 1 (1.2) | |
| TKI, n (%) | 6 (2.5) | 4 (2.5) | 2 (2.4) | 1.0 |
| erlotinib, n (%) | 1 (0.4) | 1 (0.6) | 0 | |
| lapatinib, n (%) | 4 (1.7) | 2 (1.3) | 2 (2.4) | |
| nintedanib, n (%) | 1 (0.4) | 1 (0.6) | 0 | |
| pazopanib, n (%) | 1 (0.4) | 1 (0.6) | 0 |
Targeted therapy including CDK 4/6 inhibitors (CDKi), immune checkpoint inhibitors (ICI), monoclonal antibodies (mAB), PARP-inhibitors (PARPi), TKI-inhibitors (TKI) and combinations of them; n, number; %, percent. Numbers of patients in the various therapy groups may not sum up to 100 percent as some patients have received a combination of targeted therapies.